Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia-Reference-Cited by-同舟云学术

Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia

Published:2017-12-16 Issue:3 Volume:43 Page:414-421
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Zhong W.¹,Zhang Y.¹,Zhang M.-Z.²,Huang X.-H.³,Li Y.¹,Li R.¹,Liu Q.-W.⁴

Affiliation:

1. Department of Anesthesiology; The Second Affiliated Hospital of Anhui Medical University; Hefei China

2. Pediatric Clinical Pharmacology Laboratory; Department of Anesthesiology; Shanghai Children's Medical Center; Shanghai Jiao Tong University School of Medicine; Shanghai China

3. School of Pharmacy; Inner Anhui Medical University; Hefei China

4. Center for Instrumental Analysis; China Pharmaceutical University; Nanjing China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12652/fullpdf

Reference22 articles.

1. Brown tumors in secondary hyperparathyroidism in a patient with lupus nephritis;Fernandes;J Clin Rheumatol,2016

2. Cholecalciferol additively reduces serum parathyroid hormone and increases vitamin D and cathelicidin levels in paricalcitol-treated secondary hyperparathyroid hemodialysis patients;Zheng;Nutrients,2016

3. Intraperitoneal calcitriol for treatment of severe hyperparathyroidism in children with chronic kidney disease: a therapy forgotten;Chanchlani;Perit Dial Int,2016